Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review

@article{Melani2018OlodaterolFT,
  title={Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review},
  author={Andrea S. Melani},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={1603 - 1611}
}
  • A. Melani
  • Published 22 September 2018
  • Medicine
  • Expert Opinion on Pharmacotherapy
ABSTRACT Introduction: Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management. Olodaterol 5 µg, a long-acting β2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy. Areas covered: This article reviews the several trials that have assessed olodaterol as a COPD therapy. It covers safety and tolerability data and provides the reader with an expert opinion on its use as a treatment for COPD. Expert… 

Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure.

Mechanistic insights into the application of β2-agonists in asthma, chronic obstructive pulmonary disease (COPD), and heart failure (HF), and overlap of COPD and HF are provided.

Effect of physical therapy for chronic obstructive pulmonary disease

A systematic review of randomized controlled trials of physical therapy for COPD to assess its effectiveness and safety for the treatment of patients with COPD will provide up-todated summary evidence for assessing the effectiveness and Safety.

References

SHOWING 1-10 OF 76 REFERENCES

Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease

Olodaterol was generally well tolerated and had an acceptable cardiovascular and respiratory adverse event profile, however, further longer-term and active comparator-controlled studies would be beneficial, including trials powered to assess COPD exacerbations.

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol

The results from the ongoing large TOviTO Phase III trial program have documented the efficacy and safety of olodaterol/tiotropium fixed-dose combination as maintenance therapy in patients with moderate to very severe COPD.

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

This research highlights the importance of considering the concomitant COPD medication when evaluating treatment effects in COPD, and indicates that olodaterol and indacaterol have similar efficacy in patients with COPD.

The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta‐analysis

Inhaled olodaterol has no impact on mortality risk in clinical trials conducted on patients with COPD and asthma and the interpretation is limited by a high OR (1.31) and a wide CI that includes the hazardous effect.

UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease

Tiotropium was found to reduce significantly COPD-related morbidity, to improve health-related quality of life (HRQoL) irrespective of disease severity and to slow significantly lung function decline in patients not using inhaled corticosteroids or other long-acting bronchodilators.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1).

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials demonstrate the long-term efficacy and safety of once-daily olodaterol 5 μg and 10 μg in patients with moderate to very severe COPD continuing with usual-care maintenance therapy.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.

Pharmacology and Therapeutics of Bronchodilators

An important step in simplifying asthma and COPD management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control, so the incorporation of once-daily dose administration is an important strategy to improve adherence.
...